Opendata, web and dolomites

MEPHOS SIGNED

Shaping the Mechano-Pharmacological properties of Microparticles and Extracellular Vesicles for the Treatment of Osteoarthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEPHOS project word cloud

Explore the words cloud of the MEPHOS project. It provides you a very rough idea of what is the project "MEPHOS" about.

subchondral    ambition    risk    molecules    mephos    upls    halt    translational    single    sophisticated    hydrogel    polymeric    vesicles    replacement    joint    realizing    spark    market    chronic    industrial    clinical    predicted    scientists    regeneration    context    match    aging    option    intersectoral    older    fabrication    models    academic    disease    sme    ultimately    2026    gender    weeks    action    burden    clinic    modulating    preclinical    fluid    extracellular    synovial    secondments    stanford    deposition    culture    assays    trauma    training    people    small    obesity    sole    societal    bone    bridge    clinically    translation    release    osteoarthritis    million    rational    viscoelastic    metalloproteinase    hit    articular    inhibitors    pain    oa    technologies    2016    biological    rationally    mechanical    microplates    upl    degeneration    documents    geometry    continues    interdisciplinary    billion    glycoproteins    symptoms    vitro    instil    tissue    boundaries    inclusion    chemokine    approved    simultaneously    cell    adults    pharmacological    sustainably    biologicals       strategy    stem    characterization    treatment    course    consequently    curing    rising    cartilage       options    disability   

Project "MEPHOS" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 952˙200 €
 EC max contribution 864˙800 € (91%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 312˙800.00
2    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 253˙000.00
3    UNIVERSIDADE DO MINHO PT (BRAGA) participant 225˙400.00
4    LIPOCURE LTD IL (JERUSALEM) participant 73˙600.00
5    BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY US (STANFORD) partner 0.00
6    THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL US (CHAPEL HILL) partner 0.00
7    University of Arkansas US (Fayetteville) partner 0.00
8    VANDERBILT UNIVERSITY US (NASHVILLE TENESSEE) partner 0.00

Map

 Project objective

Osteoarthritis (OA) is a chronic disease involving the degeneration of articular cartilage and subchondral bone. It represents the single most common cause of disability in older adults. Being aging, obesity, trauma and gender risk factors for OA, its societal burden is rapidly rising. Across EU, over 40 million people are affected by OA. Current treatment options aim at modulating the symptoms rather than curing this chronic disease. Consequently, joint replacement continues to be ultimately the sole option. In this context, MEPHOS aims at realizing an integrated strategy for OA treatment based on the intra-articular deposition of hydrogel, polymeric microplates (uPLs) that could simultaneously provide a long-term pharmacological action and mechanical support. To this end, the uPL geometry and mechanical properties will be rationally selected to match the viscoelastic behaviour of cartilage and synovial fluid. Over the course of several weeks, uPLs will sustainably release clinically-approved molecules for pain management and novel small molecules and biologicals; including chemokine and metalloproteinase inhibitors to halt tissue degeneration; glycoproteins, growth factors and stem cell-derived extracellular vesicles to favour tissue regeneration. MEPHOS involves three EU Academic Institutions and a SME for uPL fabrication, and four US Academic Institutions for uPL biological and preclinical characterization. Through interdisciplinary and intersectoral secondments, this project will support the training of EU scientists on sophisticated in-vitro assays and three different preclinical OA models; foster the rational development of uPLs; and instil a translational research culture to bridge preclinical-clinical boundaries. The inclusion of a SME and the Stanford SPARK Translation program documents MEPHOS ambition to develop technologies that could hit the clinic and an industrial market, which is predicted to growth from $1.6 billion in 2016 to $3.5 billion by 2026.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEPHOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEPHOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

iGame (2019)

Multi-dimensional Intervention Support Architecture for Gamified eHealth and mHealth Products

Read More  

ENDORSE (2018)

Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial Spaces

Read More